• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA expands approval of Spiriva Respimat inhalation spray for pediatric asthma

FDA expands approval of Spiriva Respimat inhalation spray for pediatric asthma

February 17, 2017
CenterWatch Staff

Boehringer Ingelheim Pharmaceuticals has announced that the FDA approved SPIRIVA RESPIMAT for the long-term, once-daily maintenance treatment of asthma in people age 6 and older. SPIRIVA RESPIMAT is not a treatment for sudden asthma symptoms.

The FDA approved the Supplemental New Drug Application (sNDA) under a priority review designation, and the FDA also granted pediatric exclusivity to SPIRIVA RESPIMAT in light of the clinical trials conducted by Boehringer Ingelheim.

SPIRIVA RESPIMAT is steroid-free and works differently from other treatment options to open airways to help people breathe better. In its comprehensive clinical trial program, SPIRIVA RESPIMAT demonstrated proven efficacy and safety for patients age 6 and older.

“It is important for healthcare providers to identify and treat patients who may be taking a controller medicine, but who continue to experience uncontrolled asthma symptoms that can make it difficult to breathe and may even cause an exacerbation,” said Bradley E. Chipps, M.D., Capital Allergy & Respiratory Disease Center, Sacramento, California. “As healthcare providers, we need options, like SPIRIVA RESPIMAT, to consider as an add-on treatment to improve asthma symptoms for the broad age range of patients who may need more control.”

SPIRIVA RESPIMAT, which is delivered as two puffs once a day of 1.25mcg per puff, is part of a class of medicines called long-acting muscarinic antagonist (LAMA) and is the only one of its kind approved for asthma. SPIRIVA RESPIMAT was approved in September 2015 for the long-term, once-daily, prescription maintenance treatment of asthma in people age 12 and older. In the treatment of asthma, the maximum benefits in breathing may take up to four to eight weeks.

Asthma is a chronic respiratory disease that can cause airways to become narrower and irritated, making it difficult to breathe. It currently affects nearly 6.3 million American children. Asthma symptoms can be serious, and uncontrolled asthma could lead to emergency room visits, hospital stays and missed days of school.

“This FDA approval expands the indication of SPIRIVA RESPIMAT to a broad range of people, including children, adolescents and adults who may be experiencing uncontrolled asthma,” said Sabine Luik M.D., senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals. “For nearly a century, Boehringer Ingelheim has been focused on addressing serious unmet needs. This approval is further evidence of our ongoing commitment to improving the lives of the patients we serve.”

This FDA approval is based on efficacy and safety data from the phase II and phase III UniTinA-asthma clinical development program, which included more than 150 sites globally with over 6,000 patients, including 804 children (aged 6-11 years).

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing